Liver Precursor Cell Isolation Using DPP4 Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating liver precursor cells and mature hepatocytes from human embryonic stem cells (hESCs) are inefficient and lack the ability to isolate and characterize intermediate cell types, limiting their therapeutic and drug study applications due to the scarcity of high-quality liver cells for transplantation and the challenges of directed differentiation.
Innovation Solution
The development of cell cultures and methods that utilize specific markers such as DPP4 and other proteins to enrich and isolate liver precursor cells, involving the use of growth factors like BMP and FGF10, and the separation of cells using reagents that bind to these markers to achieve high percentages of liver precursor and hepatocyte cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If human embryonic stem cells are used to generate liver precursor cells and hepatocytes, then the source of cells for therapy is expanded, but the efficiency of generating high-quality liver cells remains very low
Solution Approach 1:
The patent segments the differentiation process into distinct stages by identifying and isolating intermediate cell types (definitive endoderm, liver precursor cells, hepatoblasts) between hESCs and mature hepatocytes. This segmentation allows for optimized culture conditions at each stage and enables the use of specific markers to track and enhance differentiation efficiency through each transitional phase.
Solution Approach 2:
The patent employs preliminary actions by first generating and isolating definitive endoderm cells from hESCs using specific culture conditions and markers (SOX17, FOXA2) before proceeding to liver-specific differentiation. This preliminary step enriches the cell population for liver-committed progenitors, thereby improving the overall efficiency of subsequent hepatocyte generation.
2Reliability
If traditional donor liver cells are used for transplantation, then the quality of liver cells for therapy is maintained, but the scarcity of donor organs limits availability
Solution Approach 1:
The patent establishes a universal platform using hESCs that can generate unlimited quantities of liver cells through controlled differentiation. This multi-functional system can produce various liver cell types (hepatocytes, cholangiocytes, hepatic stellate cells) from a single stem cell source, thereby overcoming the scarcity of donor organs while maintaining cell quality through standardized culture protocols.
Solution Approach 2:
The patent enables self-service by developing autologous liver cell therapy where a patient's own hESCs are differentiated into liver cells and transplanted back into the same patient. This eliminates the need for donor organs and reduces immunological rejection, providing an unlimited source of personalized liver cells for therapy.
3Manufacturing precision
If markers are used to isolate liver precursor cells, then the purity of cell populations is increased, but the complexity of the isolation process increases
Solution Approach 1:
The patent utilizes parameter changes by monitoring and manipulating the expression levels of specific markers (SOX17, FOXA2, DPP4, HNF4A, AFP) at different stages of differentiation. By adjusting culture conditions (growth factors, medium composition, oxygen tension) in response to marker expression, the process achieves high purity liver cell populations through dynamic parameter optimization rather than complex physical separation devices.
Data Source
AI summary
Disclosed herein are methods for producing liver precursor cells as well as hepatocyte cells form pluripotent and/or multipotent cells. Also disclosed herein are methods of enriching isolating and/or purifying liver precursor cells and/or hepatocyte cells. Further disclosed are compositions comprising cell cultures and cell populations that are enriched for liver precursor cells or hepatocyte cells.